Search

Ingelheim, Germany, 30/10/2023 | Boehringer Ingelheim, a leading research-driven biopharmaceutical company, on Monday presented a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study

About Us

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention

Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

Hypertension

Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario

Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba

Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

Cardiovascular Optimization and Community Hub (COACH)

Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Simple and straight to the source: tips for ileitis control

Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients

Indigenous communities and partners unite to bridge gaps in healthcare through PATHWAYS initiative

Innovative health projects impact thousands of Indigenous Peoples in Canada

OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)

Research Manitoba and Boehringer Ingelheim Canada Partnership to Invest in Diabetes Care in Indigenous Populations in Manitoba

Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities

Protecting Animals and Humans

A versatile solution for PCV2 and PRRS protection

Salmonella in pigs, pork and people

Life forward - Boehringer Ingelheim unveils its evolved company brand

Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba 